CureVac N.V. (CVAC)
| Market Cap | 18.18B |
| Revenue (ttm) | 48.87M |
| Net Income (ttm) | -129.12M |
| Shares Out | 186.22M |
| EPS (ttm) | -0.98 |
| PE Ratio | n/a |
| Forward PE | 12.44 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $102.35 |
| Previous Close | $93.96 |
| Change ($) | 8.39 |
| Change (%) | 8.93% |
| Day's Open | 97.58 |
| Day's Range | 95.61 - 102.36 |
| Day's Volume | 852,033 |
| 52-Week Range | 36.15 - 151.80 |
CureVac N.V. (NASDAQ: CVAC) and GlaxoSmithKline Plc (NYSE: GSK) have released positive early data from a preclinical study of its second-generation COVID-19 vaccine with signs that the candidate could a...
BioNTech SE - ADR (NASDAQ: BNTX) shares were trading higher by 8.27% at $198.80 in Monday's premarket session after the company announced a Chinese joint venture to make 1 billion COVID-19 vaccine doses...
The promising data in mice needs to translate into humans.
Probably not, but at least one of them could make you thousands over time.
Novartis is scaling up facilities to make COVID-19 vaccine doses for German drugmaker CureVac and could boost production beyond levels agreed so far, Chief Executive Vas Narasimhan said on a conference ...
The biotech still has a long way to go to prove itself and justify its current stock valuation.
A big market is in big need of more vaccines.
CureVac in Talks With U.S. Over Next-gen Covid Shot: CEO
Apr.16 -- CureVac CEO Franz-Werner Haas says the company aims to produce 300 million doses of their mRNA-based vaccine in 2021 and is in discussions with the U.S. and other countries about supplying nex...
CureVac to Release Results of Covid Vaccine Trials
Apr.15 -- Kempen & Co Equity Analyst of Life Science Ingrid Gafanhao speaks to Bloomberg's Alix Steel about the Curevac Covid-19 vaccine and it's expected release now that variants are being taken into ...
PPD, Inc. (NASDAQ: PPD), Immunic, Inc. (NASDAQ: IMUX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and CureVac N.V. (NASDAQ: CVAC) are among the healthcare movers on Thursday.
The U.K. and EU have pre-ordered up to 455 million doses of CureVac's mRNA vaccine, subject to regulatory approval.
CureVac BV (NASDAQ: CVAC) has partnered with Celonic Group, a Contract Development, and Manufacturing Organization, to produce CureVac's mRNA-based COVID-19 vaccine candidate, CVnCoV. The commercial sup...
First challenge infection study in preclinical mouse model to provide evidence for protection against SARS-CoV-2 variant CVnCoV induces robust antibody titers with virus variant neutralizing capacity in...
CureVac BV (NASDAQ: CVAC) plans to expand and further specify the protocols of its ongoing late-stage clinical trials with CVnCoV, its COVID-19 vaccine candidate. CVnCoV efficacy is currently being eval...
Novartis (NVS) will manufacture the mRNA and bulk drug product for CureVac's COVID-19 vaccine candidate.
Swiss Pharma giant Novartis AG (NYSE: NVS) has agreed to help CureVac BV (NASDAQ: CVAC) produce its experimental COVID-19 vaccine, known as CVnCoV. Novartis plans to manufacture the mRNA molecules that ...
Coronavirus vaccine news supply deals and a regulatory filing are in the headlines in Friday's trading session. US Secures More Vaccine Doses: Moderna Inc (NASDAQ: MRNA) and Pfizer Inc. (NYSE: PFE), th...
mRNA will play a part in pandemic preparedness for the future, CureVac CEO says
Franz-Werner Haas, CEO of CureVac, discusses the future outlook for vaccines.
CureVac working on a second generation vaccine to combat Covid variants, CEO says
CureVac CEO Franz-Werner Haas discusses the firm's plans to tackle new Covid-19 variants.
The UK government has said it is to join forces with German group CureVac BV (NASDAQ:CVAC) to develop vaccines capable of dealing with mutations in the coronavirus (COVID-19) virus. Britain has initiall...
The U.K. has entered into a collaboration accord with CureVac NV (NASDAQ: CVAC) to develop messenger ribonucleic acid (mRNA)-based vaccine candidates against COVID-19 variants. CureVac will deliver an ...
CureVac Joins GlaxoSmithKline to Make Next-Gen Covid Shot
Feb.03 -- CureVac has joined forces with GlaxoSmithKline Plc to create a next-generation Covid mRNA shot that could help protect against multiple variants of the pathogen, and it's extended a partnershi...
Shares of CureVac were down 3.1% in premarket trading on Thursday after the German company said it aims to raise $450 million through a follow-up public offering. CureVac, which went public in August, p...
Investors will want to scoop up shares of this diversified drugmaker and coronavirus vaccine developer before it's too late.
CureVac shares currently trade at $100.6 - down from nearly $150 in early December. The mRNA specialist IPO'd at a price of just $16 in August last year, but shares have spiked in anticipation of an app...
CureVac partners with Bayer to accelerate vaccine production
Franz-Werner Haas, CureVac CEO says it has initiated a phase 2b-3 trial and expects to enroll 35,000 people in Europe and Latin America. He joins 'Closing Bell' to discuss.
Data provided further evidence on immunogenicity and protective efficacy of CVnCoV Induction of robust antibody and T cell responses at lower dose than tested in Phase 3 trial Full lung protection of CV...
CureVac (CVAC) gains on a collaboration agreement with Bayer (BAYRY) for further development and supply of its COVID-19 vaccine candidate, CVnCoV.
The coronavirus vaccine developer announced a new partnership with a major player on the global pharmaceutical scene.
Sometimes you need a little help from a big brother.
CureVac BV (NASDAQ: CVAC) shares have received a nice lift and breached the $100 level for the first time in the new year. What Happened: German coronavirus vaccine maker CureVac said Thursday it has si...
The shares of CureVac BV (NASDAQ:CVAC) are soaring this morning, up 18.5% at $102.88 at last check.
LOS ANGELES--(BUSINESS WIRE)---- $CVAC #COVID19--Investor's Business Daily (IBD), a leading financial news and research organization, today announced its list of the 100 Best Companies of 2020. Companie...
Companies enter into a collaboration and services agreement Bayer to support CureVac in numerous areas, including development and supply of CVnCoV CureVac benefits from Bayer's expertise and established...
German biotech firm CureVac has agreed to an alliance with drugmaker Bayer to get global support in seeking approval for its experimental COVID-19 vaccine and for distribution, the two companies said on...
German biotech firm CureVac has agreed to an alliance with drugmaker Bayer to get global support in seeking approval for its experimental COVID-19 vaccine and for distribution, daily Bild reported.
Study to assess safety and immunogenicity of CVnCoV in high-risk population group Study builds on observational epidemiological study TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / December 21, 2020 / ...
Here we discuss four small biotech companies, NVAX, CVAC, VXRT and ARCT, that are making COVID-19 vaccine candidates, which may be approved in 2021, if successfully developed, and bring profits.
CureVac (CVAC) doses the first patient in a pivotal study on its COVID-19 vaccine candidate, CVnCoV. Shares rise following this development.
CureVac N.V. (NASDAQ: CVAC) advanced in the fight against COVID-19 by beginning enrollment in its midstage vaccine candidate study.
Tübingen-based CureVac said the Phase 3 trial will include more than 35,000 volunteers in Europe and Latin America
If we judge by return on investment, these two mid-cap biotechs may be the ultimate winners of the coronavirus vaccine race.
And it's not too far behind coronavirus vaccine leaders Pfizer and Moderna.
The European Union could pay more than $10 billion to secure hundreds of millions of doses of the vaccine candidates being developed by Pfizer-BioNTech and CureVac, an EU official involved in the talks ...
Enough Pharma Capacity to Vaccinate World by End of 2021: CureVac CEO
Nov.18 -- CureVac Chief Executive Officer Franz-Werner Haas discusses the progress on the biopharmaceutical company's Covid-19 vaccine and scale-up for its production on “Bloomberg Surveillance.”
About CVAC
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenz... [Read more...]
| Industry Biotechnology | IPO Date Aug 14, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol CVAC |
Financial Performance
In 2020, CureVac's revenue was $48.87 million, an increase of 180.61% compared to the previous year's $17.42 million. Losses were -$129.12 million, 29.3% more than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for CureVac stock is "Buy." The 12-month stock price forecast is 93.82, which is a decrease of -8.33% from the latest price.